Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rxc004 + nivolumab
- Development stage
- Phase 2
- Lead developer
- Redx Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**RXC004 + nivolumab** is a combination regimen under clinical investigation for genetically selected metastatic colorectal cancer. RXC004 (Zamaporvint) is a potent, selective, orally active small molecule inhibitor of *Porcupine*, a key enzyme in the Wnt signaling pathway. Porcupine inhibition blocks release of Wnt ligands, preventing both tumor growth and immune evasion. Nivolumab is a monoclonal antibody that inhibits *Programmed cell death protein 1 (PD-1)*, restoring anti-tumor immune response. The combination aims to target both Wnt-dependent oncogenic signaling and tumor immune suppression, potentially overcoming resistance to immunotherapy in microsatellite stable colorectal cancers with RNF43 mutation or RSPO gene fusion[4][5][1][3].
- Brand names
- Zamaporvint + nivolumab
- Other names
- Porcupine inhibitor + nivolumabRXC004 in combination with nivolumabRXC-004 in combination with nivolumabRXC 004 in combination with nivolumab
02
Targets
PORCN (Porcupine protein)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on rxc004 + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rxc004 + nivolumab.